Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China Read more
USD 9.6 Bn Telecom Expense Management Market Opportunities Analyzed in a 2025-2030 Research Report by Mordor Intelligence Read more
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma Read more